Anteris Technologies is pioneering advancements in the field of transcatheter aortic valve replacement (TAVR) with its innovative DurAVR™ technology. This biomimetic transcatheter heart valve is designed as a single-piece, native-shaped structure that closely mimics the performance of a healthy aortic valve. The DurAVR™ valve aims to restore near-normal hemodynamic performance, as evidenced by clinical studies demonstrating its effectiveness in maintaining flow dynamics comparable to those of a healthy aortic valve. Key metrics such as Effective Orifice Area (EOA), Mean Pressure Gradient (MPG), and Doppler Velocity Index (DVI) indicate that the DurAVR™ THV delivers outstanding hemodynamic results, making it a promising option for patients with severe aortic stenosis.

The clinical evidence supporting DurAVR™ includes data from First-In-Human studies and Early Feasibility Studies, which highlight its high implant success rates and favorable safety profile. Notably, the studies reported no valve-related adverse events within the first year of follow-up, underscoring the valve's safety and efficacy. Anteris Technologies continues to drive awareness and adoption of its ADAPT® technology through strategic partnerships and a commitment to scientific innovation, aiming to deliver transformative solutions for patients in need of cardiac interventions.

Australia

Anteris Technologies is a structural heart company focused on developing innovative solutions to the biggest challenges facing aortic stenosis patients and their physicians. 

Our DurAVR™ Transcatheter Heart Valve (THV) System is designed for younger patients who need a heart valve that will last their lifetime.

 DurAVR™ THV is a unique, single-piece valve and its first-in-class biomimetic design replicates the normal blood flow of a healthy human aortic valve.
| $AVR | ASX: AVR | #DurAVR #ADAPT #structuralheart #TAVR #TAVI #cardiology


Anteris Technologies

Company Details